Antibody-Drug Conjugates – Special Topics – Special Topics: Trends and Market Dynamics
Antibody-drug conjugates have solidified their position as valuable tools against cancer. The agents combine the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. The approval of agents targeting various tumor-associated antigens continues to reshape the therapy landscape for many oncology indications. The late-phase pipeline is bustling with activity, with promising candidates poised to enter the market and transform treatment paradigms. This Special Topics report provides a comprehensive market forecast of current and emerging antibody-drug conjugates in select oncology indications and analyzes key market trends and dynamics.
QUESTIONS ANSWERED
- What is the current landscape for approved antibody-drug conjugates? What are their expected label expansions?
- What is the market positioning of emerging antibody-drug conjugates?
- How will the indication-specific market trends and dynamics evolve?
- What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, and geography? How will the market evolve over the 2023-2033 forecast period?
GEOGRAPHIES
United States, EU5, Japan.
EPIDEMIOLOGY
Drug-treated patient populations by brand, oncology indication, and geography.
FORECAST
10-year, annualized, drug-level sales of antibody-drug conjugates through 2033, segmented by indication and geography.
KEY DRUGS COVERED
Select approved therapies (e.g., Enhertu, Kadcyla, Trodelvy, Polivy).
EMERGING THERAPIES
Coverage of select agents in Phase 3 development.
PRODUCT DESCRIPTION
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugates landscape in select oncology indications.
